China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to initiate a Phase I/IIa clinical study for its in-house developed PARP7 inhibitor, JAB-26766, targeting advanced solid tumors.
JAB-26766: A Potential Treatment for Squamous Cancers
The oral small molecule PARP7 inhibitor is under development for the treatment of squamous non-small cell lung cancer and head and neck squamous cell carcinoma, among other solid tumors. JAB-26766 has demonstrated significant anti-tumor activities in multiple mouse tumor models, indicating its potential efficacy in treating these aggressive cancers.
Combination Therapy Prospects with JAB-X1800
The drug is expected to be assessed in combination with Jacobio’s CD73 STING-iADC, JAB-X1800, in future clinical trials. This combination therapy approach aims to enhance the treatment outcomes for patients with advanced solid tumors by leveraging the synergistic effects of two targeted therapies.-Fineline Info & Tech
